Piper Sandler Maintains Neutral on Vicarious Surgical, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder has maintained a Neutral rating on Vicarious Surgical (NYSE:RBOT) and lowered the price target from $1.5 to $1.
March 05, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler maintains a Neutral rating on Vicarious Surgical and lowers the price target from $1.5 to $1.
The reduction in price target by a reputable analyst firm like Piper Sandler could lead to a negative short-term sentiment among investors, potentially causing a decrease in RBOT's stock price. The maintenance of a Neutral rating indicates that the firm does not see significant upside or downside from the current price level, but the lowered price target suggests a revision of the expected stock performance, which could influence investor perception and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100